The effects of hyperhomocysteinemia on the microcirculation of skin flaps

Plastic and Reconstructive Surgery

Volumn 128, Issue 3, 2011, Pages

  Kamburoǧlu, Haldun O ^a   Uzun, Hakan ^a   Bitik, Ozan ^a   Ersoy, Umut S ^a   Öcal, Engin ^a   Çalş, Mert ^a   Sönmez, Erhan ^a   Şafak, Tunç ^a   Pnar, Asl ^a   Atilla, Pergin ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE;

ANIMAL; ARTICLE; BLOOD; DISEASE MODEL; GRAFT SURVIVAL; HYPERHOMOCYSTEINEMIA; MALE; MICROCIRCULATION; MICROVASCULATURE; NECROSIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PLASTIC SURGERY; RAT; SPRAGUE DAWLEY RAT; VASCULARIZATION;

ANIMALS; DISEASE MODELS, ANIMAL; GRAFT SURVIVAL; HOMOCYSTEINE; HYPERHOMOCYSTEINEMIA; MALE; MICROCIRCULATION; MICROVESSELS; NECROSIS; RATS; RATS, SPRAGUE-DAWLEY; SURGICAL FLAPS;

EID: 80052433017     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e318221db4d     Document Type: Article

References (26)

1. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med. 1991;324:1149-1155.
2. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334:759-762.
3. Guerra R Jr, Brotherton AF, Goodwin PJ, Clark CR, Armstrong ML, Harrison DG. Mechanisms of abnormal endothelium-dependent vascular relaxation in atherosclerosis: Implications for altered autocrine and paracrine functions of EDRF. Blood Vessels 1989;26:300-314.
4. Lüscher TF, Richard V, Tschudi M, Yang ZH, Boulanger C. Endothelial control of vascular tone in large and small coronary arteries. J Am Coll Cardiol. 1990;15:519-527.
5. Bertsch T, Mielke O, Höly S, et al. Homocysteine in cerebrovascular disease: An independent risk factor for subcortical vascular encephalopathy. Clin Chem Lab Med. 2001;39: 721-724.
6. Looker HC, Fagot-Campagna A, Gunter EW, et al. Homocysteine as a risk factor for nephropathy and retinopathy in type 2 diabetes. Diabetologia 2003;46:766-772.
7. Rees MJ, Taylor GI. A simplified lead oxide cadaver injection technique. Plast Reconstr Surg. 1986;77:141-145.
8. Virchow R. Phlogose und Thrombose im Gefä-system: Gesammelte Abhandlungen zur Wissenschaftlichen Medizin. Frankfurt, Germany: Staatsdruckerei; 1856.
9. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67.
10. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3=-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703.
11. Schwarz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH. Plasma protein S deficiency in familial thrombotic disease. Blood 1984;64:1297-1300.
12. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest. 1981;68:1370-1373.
13. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh. 1965;13:516-530.
14. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995;332:993-997.
15. Kamphuisen PW, Eikenboom JC, Bertina RM. Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol. 2001;21:731-738.
16. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-1057.
17. Lobo CA, Millward SF. Homocystinuria: A cause of hypercoagulability that may be unrecognized. J Vasc Interv Radiol. 1998;9:971-975.
18. Thomas RH. Hypercoagulability syndromes. Arch Intern Med. 2001;161:2433-2439.
19. Labow BI, Greene AK, Upton J. Homocystinuria: An unrecognized cause of microvascular failure. Plast Reconstr Surg. 2007;120:6e-12e.
20. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: Plasma levels in health, disease, and drug therapy. J Lab Clin Med. 1989;114:473-501.
21. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042-1050.
22. Triggle CR, Ding H, Anderson TJ, Pannirselvam M. The endothelium in health and disease: A discussion of the contribution of non-nitric oxide endothelium-derived vasoactive mediators to vascular homeostasis in normal vessels and in type II diabetes. Mol Cell Biochem. 2004;263:21-27.
23. De Vriese AS, Blom HJ, Heil SG, et al. Endothelium-derived hyperpolarizing factor-mediated renal vasodilatory response is impaired during acute and chronic hyperhomocysteinemia. Circulation 2004;109:2331-2336.
24. Abahji TN, Nill L, Ide N, Keller C, Hoffmann U, Weiss N. Acute hyperhomocysteinemia induces microvascular and macrovascular endothelial dysfunction. Arch Med Res. 2007; 38:411-416.
25. Davis MR, Shell DH IV, Marques M, Long JN. Free flap failure secondary to dual thrombophilia. Microsurgery 2009;29:62-65.
26. Broughton G II, Crosby MA, Coleman J, Rohrich RJ. Use of herbal supplements and vitamins in plastic surgery: A practical review. Plast Reconstr Surg. 2007;119:48e-66e.